Description
Veterinary Raw Powder Insecticide Fluralaner CAS 864731-61-3 99% Purity
Description
| Cas: | 864731-61-3 | MF: | C22H17Cl2F6N3O3 |
|---|---|---|---|
| MW: | 556.29 | EINECS No.: | 689-035-6 |
| Density: | 1.51±0.1 G/cm3(Predicted) | Storage: | 2-8°C |
| Shelf Life: | 2 Years | ||
| High Light: |
Veterinary Raw Powder Insecticide Fluralaner, Insecticide Fluralaner CAS 864731-61-3, 99% Purity Insecticide Fluralaner |
||
Veterinary Raw Powder Insecticide Fluralaner CAS 864731-61-3
Product introduction
| CAS | 864731-61-3 |
| Appearance | white |
| Molecular Formula | C22H17Cl2F6N3O3 |
| Molecular Weight | 556.29 |
Fluralaner (INN) is a systemic insecticide and acaricide that is administered orally or topically. The U.S. Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014 and Bravecto Plus as a topical treatment for cats in November 2019, with warnings about possible side effects in both species. The EU approved the drug in February 2014. Australia approved it for the treatment and prevention of ticks and fleas on dogs in January 2015.
Side Effects
In a well-controlled U.S. field study, which included 294 dogs (224 dogs were administered Bravecto every 12 weeks and 70 dogs were administered an oral active control every 4 weeks and were provided with a tick collar); there were no serious adverse reactions. All potential adverse reactions were recorded in dogs treated with Bravecto over a 182-day period and in dogs treated with the active control over an 84-day period. The most frequently reported adverse reaction in dogs in the Bravecto and active control groups was vomiting.
